Related Experiment Video
Updated: Aug 7, 2026
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
COX-2 upregulation in thymomas and thymic carcinomas
Ralf J Rieker1, Stefan Joos, Gunhild Mechtersheimer
1Department of General Pathology, University Hospital, Heidelberg, Germany. ralf.rieker@med.uni-heidelberg.de
International Journal of Cancer
|July 11, 2006
Summary
Cyclooxygenase-2 (COX-2) is expressed in all thymomas and thymic carcinomas, suggesting it is a potential therapeutic target alongside EGFR and KIT for these rare cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Advanced thymomas and thymic carcinomas require multimodal treatment.
- Epidermal growth factor receptor (EGFR) and KIT are investigated as therapeutic targets.
- The role of Cyclooxygenase-2 (COX-2) in thymic malignancies is currently unknown.
Purpose of the Study:
- To investigate the expression of COX-2, microsomal-PGES-1/2 (mPGES-1/2), and EGFR in thymoma and thymic carcinoma subtypes.
- To compare COX-2 expression in malignant thymic tissues with normal thymus.
Main Methods:
- Immunohistochemistry on tissue microarrays to assess protein expression.
- Western immunoblot analysis to quantify COX-2 levels.
- Comparison of expression between tumor subtypes and normal thymus.
Main Results:
- COX-2 expression was detected in all thymoma and thymic carcinoma subtypes.
- Thymomas and thymic carcinomas showed significantly higher COX-2 expression than normal thymi (p < 0.04).
- Weak correlations were observed between COX-2, mPGES-1/2, and EGFR expression levels.
Conclusions:
- COX-2 is expressed in all thymic malignancies, indicating its potential as a therapeutic target.
- Combined therapies involving COX-2 inhibitors and anti-EGFR treatments warrant further investigation.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...